מכפיל מחיר להכנסות עתידי OS Therapies, Inc. (OSTX)

OS Therapies Incorporated (OSTX) enjoys deep trust from pediatric oncologists and specialized funds as a bold scientific visionary. The business's forward P/S helps track the dynamics of this sector, and the metric has currently reached the level of . Growth is driven by FDA Fast Track designations and M&A prospects, while the strategy relies on a listeria platform to combat solid tumors.

The forward P/S ratio correlates the current market value of OS Therapies Incorporated (OSTX) with revenue forecasts, allowing for an assessment of the premium paid for future cash flows. The trend of the expected revenue multiple on GURU.Markets reflects market confidence in the success of the company's diversified oncology drug portfolio, where the distribution of risks across different trial stages directly impacts the asset's investment attractiveness.